SAN FRANCISCO, Aug. 3, 2018 /PRNewswire/ -- Xcell Biosciences, an innovator in primary cell technologies for patient-centricresearch and immunotherapy development, announces the expansion of our global sales network to support growing sales in Europe, Middle East and Asia. These global companies are leaders
The growing distributor network includes over 10 partners representing Xcell Biosciences in Switzerland, United Kingdom, Germany, Austria, France, Czech Republic and other Eastern European geographies, Israel, Japan, Singapore, South Korea, Belgium, The Netherlands, Luxembourg, Scandinavia and China.
Philippe Loir, General Manager of Sopachem in Belgium made the following statement when asked why he joined the global Xcell Biosciences network, "At Sopachem, we're always on the lookout for new technologies with the potential to disrupt established markets. Because innovation doesn't sell itself, this often means a lengthy struggle of pioneering work, which many distributors would shy away from. We know from experience that there is nothing more rewarding than being part of a successful company launch. Representing the AVATAR™ with strong support from the Xcell Bioscience family, we have all the right elements in place to bring this innovation to our scientists. We are pleased to bring the AVATAR solution to the emergent market growth we are experiencing in stem cell research, immune therapy and oncology research. The entire Sopachem team is geared up for this adventure and we're on our way to break record sales for a new supplier in the first year."
The AVATAR cell control system enables fine control of cell state enabling powerful capabilities such as rapid expansion of challenging cell types, and phonotypic control for tuning pathway expression, metabolic activity and even differentiation speed. This control is achieved through fine-tuning of both pressure and oxygen to better control the cellular environment, allowing you to mimic the range of cellular conditions found in the human body for more biologically relevant cells and more predictive research. The AVATAR improves the efficiency of workflows for primary immune, tumor and stem cells, enabling relevant patient-derived disease research, drug dosing and response in patient-derived cells, and even faster cell manufacturing times for cell therapies.
View original content:http://www.prnewswire.com/news-releases/xcell-biosciences-announces-expanding-global-distributor-network-to-support-the-avatar-cell-control-system-for-immunotherapy-applications-300691777.html
SOURCE Xcell Biosciences
Subscribe to our Free Newsletters!